Released: ·Last reviewed: ·Methodology v4.1
Scoring methodology
How Transparent Peptide scores telehealth providers: methodology v4.1, seven weighted categories worth 100 points, published before any ranking is written, with evidence and confidence levels behind every score.
How are the categories weighted?
| Category | Points | What we assess |
|---|---|---|
| Pricing transparency | 20 | Starting, renewal and highest-dose price printed before intake; all required fees; billing basis stated (per month, per 4 weeks or prepaid) |
| Total annual cost | 20 | Twelve months at a maintenance dose, membership and required fees included, on the plan a patient can actually buy |
| Clinical oversight | 15 | Licensed prescriber review, eligibility screening, follow-up access, a named medical lead with a verifiable NPI |
| Pharmacy transparency | 15 | Named dispensing pharmacy, verifiable state licence, accurate 503A/503B description, disclosed formulation |
| Support | 10 | Contact channels, response times, refill and dose-change support |
| Regulatory disclosure | 10 | Says compounded drugs are not FDA-approved; no 'generic' or trial-transfer claims; current FDA context |
| Accessibility | 10 | States served, payment options (FSA/HSA, instalments), cancellation terms, no prepay required to start |
| Total | 100 | NexLife scores 94/100 under v4.1. Other programs carry their earlier scores until their v4.1 re-score is published. |
Price pages also apply five published price checks: billed by the month, medication and care in one price, the same price at every dose, no membership, and a first-party read of the provider’s own page.
How confident are we, and on what evidence?
Every score carries a source, a capture date, a reviewer and a confidence level. A provider does not earn full points for an unverifiable claim; we mark facts Verified, Reported, Not disclosed or Contradicted.
Independence and conflicts
Advertising or affiliate relationships never change a score, rank or inclusion. The publisher has a financial relationship with NexLife, which is our editorial #1 pick; that relationship is described on the conflicts-of-interest page, and one affiliate disclosure appears in the footer of every page. Other programs are listed alphabetically after NexLife while their v4.1 re-scores are pending.
Price normalization
We normalize total cost across covered doses and required fees using one formula, computed for the initial month, ongoing month and 3-, 6- and 12-month totals. See price-verification methodology.
Version history
Methodology v4.1 — adopted October 15, 2026, replacing v1.0 (released July 12, 2026, six categories). Changes to weights or definitions trigger a version increment and re-scoring, logged in the methodology changelog.